Tag: mismatch

Cardiology

Patient prosthes is mismatch in stented biologic aortic valve prosthesis: 10 years' results.

Newsemia
Related Articles Patient prosthes is mismatch in stented biologic aortic valve prosthesis: 10 years’ results. Rev Port Cir Cardiotorac Vasc. 2019 Apr-Jun;26(2):101-107 Authors: Madeira M,...
Cardiology

Impact of Prosthesis-Patient Mismatch on 1-Year Outcomes after Transcatheter Aortic Valve Implantation: Meta-analysis of 71,106 Patients.

Newsemia
Related Articles Impact of Prosthesis-Patient Mismatch on 1-Year Outcomes after Transcatheter Aortic Valve Implantation: Meta-analysis of 71,106 Patients. Braz J Cardiovasc Surg. 2019 06 01;34(3):318-326...
Cardiology

Prosthesis-Patient Mismatch after Surgical Aortic Valve Replacement: Neither Uncommon nor Harmless.

Newsemia
Related Articles Prosthesis-Patient Mismatch after Surgical Aortic Valve Replacement: Neither Uncommon nor Harmless. Braz J Cardiovasc Surg. 2019 06 01;34(3):361-365 Authors: Rayol SDC, Sá MPBO,...
Latest News

Statistical diagnosis of process-model mismatch by means of the Lagrange multiplier test

Newsemia
Quaglio, M; Fraga, E; Galvanin, F; (2019) Statistical diagnosis of process-model mismatch by means of the Lagrange multiplier test. In: Kiss, Anton and Zondervan, Edwin...
Cardiology

A match not made in heaven-TAVR prosthesis-patient mismatch with contemporary valves.

Newsemia
Related Articles A match not made in heaven-TAVR prosthesis-patient mismatch with contemporary valves. Catheter Cardiovasc Interv. 2019 Apr 01;93(5):980-981 Authors: Safi LM, Turi ZG Abstract...
Cardiology

Prosthesis-patient mismatch after transcatheter aortic valve replacement: prevalence and medium term prognostic impact.

Newsemia
Related Articles Prosthesis-patient mismatch after transcatheter aortic valve replacement: prevalence and medium term prognostic impact. Int J Cardiovasc Imaging. 2019 Jan 19;: Authors: León Del...
Gastroenterology

Neoadjuvant ipilimumab-nivolumab combination induces major pathological response in mismatch repair-deficient colon cancer

Newsemia
MUNICH — Neoadjuvant treatment with nivolumab and ipilimumab induced major pathologic response in 100% of patients with early-stage, mismatch repair-deficient colon cancers, according to results...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy